GeDDiS: insight into frontline therapy in soft tissue sarcoma

Tap, William D.

doi:10.1016/s1470-2045(17)30672-1

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that the combination should not be recommended as routine in the first‐line setting for patients with advanced soft‐tissue sarcoma. This conclusion has however been challenged, as some oncologists believe that the combination of gemcitabine‐docetaxel could be used in the first line setting on a histology‐ driven basis …”

Section: Leiomyosarcomamentioning

confidence: 99%

Systemic therapy in retroperitoneal sarcoma management

Constantinidou

Jones

2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas comprising liposarcomas and leiomyosarcomas are by and large chemotherapy insensitive. There is an urgent need for more efficacious systemic therapies in the management of early and advanced stage retroperitoneal sarcomas.

show abstract

Section: Leiomyosarcomamentioning

confidence: 99%

Systemic therapy in retroperitoneal sarcoma management

Constantinidou

Jones

2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…On the other hand, standard first-line chemotherapy for disseminated or unresectable disease generally involves palliative systemic chemotherapy regimens with poor prognosis with a median overall survival (OS) of ∼12 months [ 10 ]. The most active first-line chemotherapy for advanced or recurrent disease has not changed for the last ∼30 years and remains doxorubicin with or without ifosfamide [ 11 ] and other nonapproved active but more toxic treatments such as gemcitabine alone or in combination with docetaxel [ 12 , 13 , 14 ]. A variety of newer cytotoxic agents, including trabectedin, pazopanib, and olaratumab, have already been approved by the US Food and Drug Administration (FDA), whilst others such as targeted therapies, aromatase inhibitors, and immunotherapies have demonstrated very modest activity in uLMS and are still under active investigation.…”

Section: Introductionmentioning

confidence: 99%

Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report

et al. 2018

View full text Add to dashboard Cite

Background: Uterine leiomyosarcoma (uLMS) is a rare tumor that accounts for 1% of all uterine malignancies. In spite of adequate surgical resection of uLMS, even in the early stage, patients remain at high risk for local and distant recurrence. Therefore, the treatment of advanced uLMS represents a considerable challenge. Methods: We report the case of a 47-year-old woman who presented with uLMS with abnormal vaginal bleeding. Results: The patient underwent a total hysterectomy and bilateral adnexectomy, which was followed by 1 year progression-free survival without adjuvant therapy. Thereafter, new lung metastases and local progression at the vaginal stump were observed. Chemotherapy with ifosfamide and doxorubicin was administered. However, after 4 cycles, a CT scan revealed disease progression in the lung metastases. Subsequently, the patient was treated with trabectedin at a dose of 1.5 mg/m² for 6 cycles resulting in complete remission of the lung metastases as well as partial remission of the mass in the vaginal stump after 9 cycles of trabectedin. The patient is currently on maintenance therapy with trabectedin and has no recurrence. Conclusion: Trabectedin seems to be an efficient option for patients with uLMS as demonstrated by a long-lasting response in a pretreated patient with an acceptable safety profile with no signs of cumulative toxicity.

show abstract

“…While no survival or progression-free survival differences were found between the groups, patients who received gemcitabine + docetaxel experienced more dose modifications and treatment discontinuation due to toxicity, as well as lower quality of life scores. While the GeDDiS trial did not report a statistically significant difference in progression-free survival between the treatment arms, some physicians may have interpreted this as meaning gemcitabine + docetaxel was still a viable treatment option [22].…”

Section: Sarcomamentioning

confidence: 98%

Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Nadler

Aguilar

Wentworth

et al. 2020

Sarcoma

View full text Add to dashboard Cite

Introduction. is study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) and to examine treatment and healthcare resource utilization patterns of this patient population in a United States (US) community-based oncology practice setting over time. Methods and Materials. A retrospective observational study was conducted within the US Oncology Network (USON). Patients were eligible if they were diagnosed with advanced or metastatic STS and were treated at a USON site between 01 July 2015 and 31 August 2018. Demographic, clinical, and treatment characteristics were described for the overall study population. Comparisons between patients by time period (prior to and after October 2016) were evaluated using the T test for continuous variables and chi-squared test for categorical variables. Data were available for analysis through 31 August 2018. Results. Demographic and clinical characteristics of the eligible study cohort (N � 376) were similar between patients who initiated treatment before and after October 2016 (all p > 0.05). Forty-three unique regimens were observed in the first-line setting, with the predominant regimen (gemcitabine + docetaxel) received by 33.2% (n � 125) patients. Prior to October 2016, 45.4% of patients received first-line gemcitabine + docetaxel, while 29.0% received this regimen after October 2016. Conclusions. While demographic and clinical characteristics were similar, treatment patterns changed in 2016. Future research should evaluate the impact of changing drug approvals and clinical trial results on future treatment patterns.

show abstract

GeDDiS: insight into frontline therapy in soft tissue sarcoma

Cited by 4 publications

References 9 publications

Systemic therapy in retroperitoneal sarcoma management

Systemic therapy in retroperitoneal sarcoma management

Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report

Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Contact Info

Product

Resources

About